Ozmosi | KFA-115 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

KFA-115

Alternative Names: KFA-115, KFA 115, KFA115, NVP-KFA115
Clinical Status: Inactive
Latest Update: 2026-01-06
Latest Update Note: Clinical Trial Update

Product Description

KFA-115, also known as NVP-KFA115, is an immunomodulatory agent being developed by Novartis for the treatment of select advanced cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05544929?term=KFA-115&draw=2&rank=1)

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Unknown

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for KFA-115

Countries in Clinic: Canada, China, France, Germany, Hong Kong, Italy, Japan, Korea, Singapore, South Korea, Spain, Taiwan, United States, Unknown Location

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Anus Cancer|Clear Cell Adenocarcinoma|Colorectal Cancer|Cutaneous Squamous Cell Carcinoma|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Kidney Cancer|Melanoma|Mesothelioma|Nasopharyngeal Cancer|Non-Small-Cell Lung Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Renal Cell Carcinoma|Skin Cancer|Squamous Cell Carcinoma|Thymoma|Thymus Cancer|Triple Negative Breast Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05544929

CKFA115A12101

P1

Active, not recruiting

Cutaneous Squamous Cell Carcinoma|Nasopharyngeal Cancer|Thymoma|Gastrointestinal Cancer|Kidney Cancer|Triple Negative Breast Cancer|Skin Cancer|Ovarian Cancer|Colorectal Cancer|Squamous Cell Carcinoma|Melanoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Mesothelioma|Esophageal Cancer|Renal Cell Carcinoma|Thymus Cancer|Clear Cell Adenocarcinoma|Anus Cancer

2027-09-01

12%

2026-01-07

Patient Enrollment|Primary Endpoints|Treatments|Trial Status

jRCT2031230410

jRCT2031230410

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

2025-12-31

CTR20250770

CTR20250770

P1

Active, not recruiting

Oncology Solid Tumor Unspecified

None

2025-12-21

Recent News Events

Date

Type

Title